Categories

ASTRAZENECA – First in class Forxiga (dapagliflozin) approved in Europe – Diabetes portfolio may heal AstraZeneca’s pains

US$ 90

BMY and AstraZeneca jointly announced the approval of its First in class SGLT-2 inhibitor Forxiga (Dapagliflozin) once daily for the treatment of Type 2 diabetes in Europe.

07-21 2015   Pages: 3

Celgene – ABRAXANE + Pipeline Drugs = Long Term Growth!

US$ 140

Despite setback to Revlimid’s label expansion in 1st line RRMM and as maintenance therapy in EU, Celgene (CELG) 3Q12 earnings highlighted growth of Revlimid globally on both a YoY and sequential basis. We do not see risk to Revlimid’s growth for at least the next 4 years and expect double digit sales CAGR,

07-21 2015   Pages: 7

RANBAXY – Market Perform, Inline Q3 CY12 results – Base business margin improvement still awaited

US$ 140

“We reiterate our Market Perform rating on Ranbaxy post its Q3 CY12 result that was largely in line with our estimates. Going forward in FY 2013, the launch of Cip-Isotretinion (4Q-2012), Tricor (Jan-2013), and Diovan (Anytime) in the US market will help Ranbaxy reasonably compensate the loss of Lipitor Exclusivity. In the conference call, Ranbaxy indicated that they expect Cip-Isotretinoin to generate $50m in sales annually. We are cautious and believe the estimates are optimistic as it would be difficult for Ranbaxy to carve a significant share of Cip-Isotretinion market, where existing players (Mylan and Teva) are well entrenched.

07-21 2015   Pages: 6

GALAPAGOS – Poised to Oust Pfizer’s Xeljanz (tofacitinib) and Other Oral JAKs on Efficacy and Safety

US$ 140

Galapagos (GLPG) released latest PhIIa data of GLPG0634 (PhII, a selective JAK1 inhibitor, partnered with Abbott for RA), where efficacy and safety were confirmed with sustained and statistically significant improvement in ACR, CRP, DAS28, and HAQ-DI response rates at the 300mg dose with no new safety signals in a larger population (91 pts).

07-21 2015   Pages: 3

AMGEN- Launched Products + Geographical Expansion Should Sustain the Growth Momentum

US$ 140

We expect Amgen (AMGN) to strengthen further from executing its near term strategy of – (i) optimizing sales force, (ii) expand direct-to-customer (DTC) advertising, and (iii) assuring appropriate access of the products in the US.

07-21 2015   Pages: 7

BIOGEN IDEC – Diversification and Strong Foothold in MS to Reign

US$ 90

We continue to like Biogen Idec (BIIB) as next year is also going to be eventful: Approval and launch of BG-12 (dimethyl fumerate, under review with FDA & EMEA, est. PDUFA: late Mar. 2013, peak sales potential ww – $2.5b by 2018) and clinical news flow from its late stage pipeline products.

07-21 2015   Pages: 4

NOVARTIS, SERELAXIN (RLX-030) in Acute Heart Failure – Significant Mortality benefit and unmet need would allow better commercial opportunity

US$ 90

Novartis released final outcome data from Phase-3 study (RELAX-AHF) exploring Serelaxin in Acute Decompensated Heart Failure patients at AHA. Although RLX-30 demonstrated a 37% statistically significant reduction mortality risk, there is criticism around the strength of this evidence.

07-21 2015   Pages: 2

PFIZER, Xeljanz (tofacitinib) approved for RA, but we see limited potential

US$ 90

Pfizer has been granted FDA approval for Xeljanz (tofacitinib) 5 mg twice daily for the treatment of adults with moderate to severe active rheumatoid arthritis who had an inadequate response or is intolerant to methotrexate (MTX).

07-21 2015   Pages: 2

CIPLA– Market Perform, Great Result But Not Completely Sustainable

US$ 140

Q2FY13 result was ahead of our estimates largely on account of higher than expected export formulation sales led by generic Lexapro (under 180-day) and improvement in Q-o-Q EBITDA margin by 330 bps. Part of the EBITDA margin improvement was ascribed to rationalization of procedures. We also consider Indore SEZ to have aided the margin of the company.

07-21 2015   Pages: 9

DISHMAN – Underperform, Management Accepts the Limitations of Pure Play CRAMS

US$ 140

Dishman’s Q2 FY13 result was largely in line with our estimates. Sales and EBITDA declined Q-o-Q by 6% and 22% respectively largely because of the decline in Carbogen Amcis and Marketable Molecules (MM). Q-o-Q EBITDA margin declined by 450 bps mainly as Q1 had the flow through effect of $5m research income. This is despite the fact that ~10% of Q2 FY13 EBITDA is coming from forex gains as against a forex loss in Q1 FY13.

07-21 2015   Pages: 6
Contact With Us
Join templatemonster at google+
Customized Research
Request Sample